Trial Site Detail
Drug: |
Imatinib, Nilotinib |
|||
|---|---|---|---|---|
Trial: |
REGISTER: A multicentre phase 2 study of risk evaluation in GIST with selective therapy escalation for response |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Completed |
|||
Border Medical Oncology69 Nordsvan Drive |
Principal Investigator: |
Craig Underhill, MD |
|---|---|
Contact: |
|
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Border Medical Oncology Website: |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.